Apilimod
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Apilimod
- DrugBank Accession Number
- DB05611
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Apilimod (DB05611)
- Weight
- Average: 418.501
Monoisotopic: 418.211724101 - Chemical Formula
- C23H26N6O2
- Synonyms
- Apilimod
- External IDs
- STA 5326
- STA-5326
Pharmacology
- Indication
Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Apilimod mesylate 5G3P5OK11S 870087-36-8 GAJWNIKZLYZYSY-OKUPSQOASA-N
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- GFW2K84S4L
- CAS number
- 541550-19-0
- InChI Key
- HSKAZIJJKRAJAV-KOEQRZSOSA-N
- InChI
- InChI=1S/C23H26N6O2/c1-18-5-4-6-19(15-18)17-25-28-21-16-22(29-10-13-30-14-11-29)27-23(26-21)31-12-8-20-7-2-3-9-24-20/h2-7,9,15-17H,8,10-14H2,1H3,(H,26,27,28)/b25-17+
- IUPAC Name
- 4-{6-[(E)-2-[(3-methylphenyl)methylidene]hydrazin-1-yl]-2-[2-(pyridin-2-yl)ethoxy]pyrimidin-4-yl}morpholine
- SMILES
- CC1=CC=CC(\C=N\NC2=CC(=NC(OCCC3=CC=CC=N3)=N2)N2CCOCC2)=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 8348782
- ChEMBL
- CHEMBL4297643
- ZINC
- ZINC000011726230
- Wikipedia
- Apilimod
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Not Available Crohn's Disease (CD) 1 2 Completed Treatment Active, Moderate to Severe Rheumatoid Arthritis 1 2 Completed Treatment Crohn's Disease (CD) 2 2 Recruiting Treatment Coronavirus Disease 2019 (COVID‑19) 1 1 Active Not Recruiting Treatment Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin 1 1 Completed Treatment Common Variable Immune Deficiency (CVID) 1 1, 2 Completed Treatment Crohn's Disease (CD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0278 mg/mL ALOGPS logP 3.91 ALOGPS logP 4.82 ChemAxon logS -4.2 ALOGPS pKa (Strongest Acidic) 14.42 ChemAxon pKa (Strongest Basic) 5.89 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 8 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 84.76 Å2 ChemAxon Rotatable Bond Count 8 ChemAxon Refractivity 123.26 m3·mol-1 ChemAxon Polarizability 45.92 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created on November 18, 2007 18:26 / Updated on February 21, 2021 18:51